Simulations PlusSLP
SLP
About: Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Employees: 247
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,200% more call options, than puts
Call options by funds: $91K | Put options by funds: $7K
34% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 44
4.89% more ownership
Funds ownership: 79.07% [Q4 2024] → 83.96% (+4.89%) [Q1 2025]
3% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 29
2% less funds holding
Funds holding: 165 [Q4 2024] → 161 (-4) [Q1 2025]
7% less capital invested
Capital invested by funds: $443M [Q4 2024] → $414M (-$29.5M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
89%
upside
Avg. target
$38
99%
upside
High target
$40
110%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Matt Hewitt | 89%upside $36 | Buy Maintained | 13 Jun 2025 |
Keybanc Scott Schoenhaus | 110%upside $40 | Overweight Maintained | 16 Apr 2025 |
Financial journalist opinion
Based on 7 articles about SLP published over the past 30 days
Negative
Seeking Alpha
2 days ago
Simulations Plus: Further Downside Is Likely (Rating Downgrade)
Simulations Plus' Q3 FY25 results missed expectations, with revenue guidance cut sharply due to biopharma market weakness and services segment volatility. Organic growth continues to decelerate and the company's margins are under pressure. This situation is likely to persist, while the demand environment is soft. Simulations Plus' revenue multiple remains high, given its dependence on services and reliance on M&A to drive growth. As a result, further downside appears likely.
Negative
Benzinga
2 days ago
Simulations Plus Slashes Guidance Amid Biotech Spending Cuts, Analyst Expresses Doubt
Simulations Plus Inc SLP stock tanked after the company lowered its fiscal 2025 sales outlook.
Negative
Zacks Investment Research
3 days ago
SLP Cuts FY25 Revenue Outlook, Begins Strategic Reorganization
Simulations Plus lowers FY25 revenue forecast and restructures operations as biotech headwinds hit services demand.
Neutral
Business Wire
3 days ago
Simulations Plus to Participate in the Citizens Medical Devices and Healthcare Services Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O'Connor will host one-on-one.
Neutral
Business Wire
3 days ago
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 mil.
Neutral
Business Wire
1 week ago
Simulations Plus Releases ADMET Predictor® 13
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of ADMET Predictor® 13, its flagship machine learning (ML) modeling platform for the design, optimization, and selection of new molecules during various stages of drug discovery. ADMET Predictor 13.
Positive
Zacks Investment Research
3 weeks ago
SLP Advances Predictive Toxicology With DILIsym 11: Shares to Benefit?
Simulations Plus unveils DILIsym 11, an upgraded version of its flagship QST platform to advance predictive toxicology and pediatric liver assessment safety.
Neutral
Business Wire
1 month ago
Simulations Plus Releases DILIsym® 11
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of DILIsym® 11, the latest version of its flagship quantitative systems toxicology (QST) platform. “Advancing toxicology research and improving the prediction of drug-induced liver injury (DILI) are.
Neutral
Business Wire
1 month ago
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i.
Positive
Seeking Alpha
1 month ago
Simulations Plus: Benefiting From FDA Modernization And AI
Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation.
Charts implemented using Lightweight Charts™